Global Oligonucleotide-based Therapies Market Research Report 2024

Publication ID:

PB505251035

Publication Date:

May 10, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
The global Oligonucleotide-based Therapies market was valued at US$ 3678.1 million in 2023 and is anticipated to reach US$ 7749.8 million by 2030, witnessing a CAGR of 11.0% during the forecast period 2024-2030.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide-based Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide-based Therapies.
Report Scope
The Oligonucleotide-based Therapies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oligonucleotide-based Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide-based Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Segment by Application
Neuromuscular Diseases
Hepatic VOD
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide-based Therapies companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide-based Therapies Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antisense Oligonucleotide
1.2.3 Aptamer
1.2.4 Other
1.3 Market by Application
1.3.1 Global Oligonucleotide-based Therapies Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Neuromuscular Diseases
1.3.3 Hepatic VOD
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide-based Therapies Market Perspective (2019-2030)
2.2 Oligonucleotide-based Therapies Growth Trends by Region
2.2.1 Global Oligonucleotide-based Therapies Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oligonucleotide-based Therapies Historic Market Size by Region (2019-2024)
2.2.3 Oligonucleotide-based Therapies Forecasted Market Size by Region (2025-2030)
2.3 Oligonucleotide-based Therapies Market Dynamics
2.3.1 Oligonucleotide-based Therapies Industry Trends
2.3.2 Oligonucleotide-based Therapies Market Drivers
2.3.3 Oligonucleotide-based Therapies Market Challenges
2.3.4 Oligonucleotide-based Therapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide-based Therapies Players by Revenue
3.1.1 Global Top Oligonucleotide-based Therapies Players by Revenue (2019-2024)
3.1.2 Global Oligonucleotide-based Therapies Revenue Market Share by Players (2019-2024)
3.2 Global Oligonucleotide-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oligonucleotide-based Therapies Revenue
3.4 Global Oligonucleotide-based Therapies Market Concentration Ratio
3.4.1 Global Oligonucleotide-based Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide-based Therapies Revenue in 2023
3.5 Oligonucleotide-based Therapies Key Players Head office and Area Served
3.6 Key Players Oligonucleotide-based Therapies Product Solution and Service
3.7 Date of Enter into Oligonucleotide-based Therapies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide-based Therapies Breakdown Data by Type
4.1 Global Oligonucleotide-based Therapies Historic Market Size by Type (2019-2024)
4.2 Global Oligonucleotide-based Therapies Forecasted Market Size by Type (2025-2030)
5 Oligonucleotide-based Therapies Breakdown Data by Application
5.1 Global Oligonucleotide-based Therapies Historic Market Size by Application (2019-2024)
5.2 Global Oligonucleotide-based Therapies Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oligonucleotide-based Therapies Market Size (2019-2030)
6.2 North America Oligonucleotide-based Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oligonucleotide-based Therapies Market Size by Country (2019-2024)
6.4 North America Oligonucleotide-based Therapies Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide-based Therapies Market Size (2019-2030)
7.2 Europe Oligonucleotide-based Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oligonucleotide-based Therapies Market Size by Country (2019-2024)
7.4 Europe Oligonucleotide-based Therapies Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide-based Therapies Market Size (2019-2030)
8.2 Asia-Pacific Oligonucleotide-based Therapies Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oligonucleotide-based Therapies Market Size by Region (2019-2024)
8.4 Asia-Pacific Oligonucleotide-based Therapies Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oligonucleotide-based Therapies Market Size (2019-2030)
9.2 Latin America Oligonucleotide-based Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oligonucleotide-based Therapies Market Size by Country (2019-2024)
9.4 Latin America Oligonucleotide-based Therapies Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide-based Therapies Market Size (2019-2030)
10.2 Middle East & Africa Oligonucleotide-based Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oligonucleotide-based Therapies Market Size by Country (2019-2024)
10.4 Middle East & Africa Oligonucleotide-based Therapies Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Oligonucleotide-based Therapies Introduction
11.1.4 Biogen Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.1.5 Biogen Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Detail
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Oligonucleotide-based Therapies Introduction
11.2.4 Sarepta Therapeutics Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.2.5 Sarepta Therapeutics Recent Development
11.3 Jazz Pharmaceuticals
11.3.1 Jazz Pharmaceuticals Company Detail
11.3.2 Jazz Pharmaceuticals Business Overview
11.3.3 Jazz Pharmaceuticals Oligonucleotide-based Therapies Introduction
11.3.4 Jazz Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.3.5 Jazz Pharmaceuticals Recent Development
11.4 Bausch & Lomb
11.4.1 Bausch & Lomb Company Detail
11.4.2 Bausch & Lomb Business Overview
11.4.3 Bausch & Lomb Oligonucleotide-based Therapies Introduction
11.4.4 Bausch & Lomb Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.4.5 Bausch & Lomb Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Detail
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Dynavax Technologies
11.6.1 Dynavax Technologies Company Detail
11.6.2 Dynavax Technologies Business Overview
11.6.3 Dynavax Technologies Oligonucleotide-based Therapies Introduction
11.6.4 Dynavax Technologies Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.6.5 Dynavax Technologies Recent Development
11.7 Kastle therapeutics
11.7.1 Kastle therapeutics Company Detail
11.7.2 Kastle therapeutics Business Overview
11.7.3 Kastle therapeutics Oligonucleotide-based Therapies Introduction
11.7.4 Kastle therapeutics Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.7.5 Kastle therapeutics Recent Development
11.8 Akcea Therapeutics
11.8.1 Akcea Therapeutics Company Detail
11.8.2 Akcea Therapeutics Business Overview
11.8.3 Akcea Therapeutics Oligonucleotide-based Therapies Introduction
11.8.4 Akcea Therapeutics Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.8.5 Akcea Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂